ArticleACS catalysis2025
High-Throughput Enabled Iridium-Catalyzed C-H Borylation Platform for Late-Stage Functionalization.
Article in ACS catalysis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this work, we present a dedicated, high-throughput reaction optimization platform allowing for the rapid evaluation of regiodivergent C-H borylation protocols while minimizing the amount of starting material required. The workflow was applied to a diverse set of fragment-like compounds, pharmaceuticals, and agrochemicals, and its practicality was demonstrated by successfully isolating 36 derivatives of bioactive compounds. Leveraging the informer library approach, we provide a comprehensive, side-by-side comparison of catalytic methods, revealing insights into the strengths, limitations, and versatility of each borylation protocol. Surprising reactivity patterns, effectiveness of ligand-free C-H borylation, and the utility of previously reported directed C-H borylation catalysts outside of their expected substrate scope have been noticed. This study highlights the potential of dedicated high-throughput optimization platforms to expand the practical utility of late-stage functionalization protocols for pharmaceutical and agrochemical research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.